학술논문
Effect of fluticasone propionate/salmeterol (250/50[mu]g) or salmeterol (50[mu]g) on COPD exacerbations
Document Type
Report
Author
Source
Respiratory Medicine. August, 2008, Vol. 102 Issue 8, p1099, 10 p.
Subject
Language
English
ISSN
0954-6111
Abstract
To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.rmed.2008.04.019 Byline: Gary T. Ferguson (a), Antonio Anzueto (b), Richard Fei (c), Amanda Emmett (d), Katharine Knobil (d), Christopher Kalberg (d) Abbreviations: COPD, chronic obstructive pulmonary disease; FEV.sub.1, forced expiratory volume in one second; FSC, fluticasone propionate/salmeterol combination; FVC, forced vital capacity Abstract: COPD exacerbations are associated with significant morbidity and mortality. This randomized, double-blind, parallel-group, multicenter study evaluated the effect of fluticasone propionate/salmeterol 250/50 and salmeterol 50[mu]g twice daily on moderate to severe exacerbations. Author Affiliation: (a) Pulmonary Research Institute of Southeast Michigan, 28807 Eight Mile Road, Suite 103, Livonia, MI 48152, USA (b) University of Texas Health Science Center at San Antonio 111 E, 7400 Merton Minter Blvd, San Antonio, TX 78230, USA (c) Bendel Medical Associates, 227 Bendel Road, Suite 300, Lafayette, LA 70503, USA (d) GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709, USA Article History: Received 22 January 2008; Accepted 18 April 2008 Article Note: (footnote) [star] ClinicalTrials.gov identifier # NCT00144911.